Amgen dismisses bone density concerns related to its weight-loss …
1 day ago · Nov 13 (Reuters) - Amgen (AMGN.O) said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after those concerns wiped off more than $12 ...
Amgen speaks out about bone density concerns with obesity drug
9 hours ago · AMGN. Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe. The company has tried to ...
Amgen stock falls as analysts mull over weight loss drug’s bone …
2 days ago · Shares of Amgen fell more than 7% Tuesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the ...
Amgen Defends Its Investigational Monthly Weight Loss Injection …
1 day ago · On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. On Wednesday, Amgen Inc ...
Amgen taking different path to weight loss windfall | Reuters
Feb 6 (Reuters) - The popularity of a new generation of weight-loss medicines is inspiring a growing number of drugmakers to pursue paths emulating Eli Lilly's (LLY.N) highly-effective...
Amgen Puts Its Weight Behind Obesity Drug With Potential ... - MedCity News
Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds. Amgen is confident its injectable obesity drug would have a differentiated profile compared to...
Amgen obesity drug MariTide: four key questions going forward
May 3, 2024 · Mark J. Terrill/AP. A mgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity drug have quickly sparked immense investor interest in what could be a potential...
Amgen scraps experimental weight loss pill, moves forward with …
May 2, 2024 · Patients given the highest dose of Amgen’s MariTide — 420 milligrams — every month lost 14.5% of their body weight on average in just 12 weeks, according to data from the phase one trial...
Amgen's potential Ozempic competitor sends stock up 13
May 3, 2024 · Amgen's potential weight loss drug is heading to a larger phase 3 trial. By. Bruce Gil. Published May 3, 2024. Topline results of Amgen’s phase 2 trial of its experimental weight loss drug,...
AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT …
Dec 1, 2022 · Amgen moved into this Phase 1 study based on human genetic insights and preclinical evidence that suggested synergistic effects with GIP receptor blockade and GLP-1 receptor agonism on weight loss and improvement in other metabolic parameters.